ABION Inc. (KOSDAQ:203400)
South Korea · Delayed Price · Currency is KRW 3,655.00
+5.00 (0.14%)
At close: Jan 28, 2026
ABION Revenue
ABION had revenue of 162.04M KRW in the quarter ending September 30, 2025, with 6.68% growth. This brings the company's revenue in the last twelve months to 1.03B, up 24.37% year-over-year. In the year 2024, ABION had annual revenue of 759.68M, down -40.38%.
Revenue (ttm)
1.03B
Revenue Growth
+24.37%
P/S Ratio
327.61
Revenue / Employee
n/a
Employees
n/a
Market Cap
337.88B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 759.68M | -514.62M | -40.38% |
| Dec 31, 2023 | 1.27B | -1.23B | -49.16% |
| Dec 31, 2022 | 2.51B | 868.02M | 52.98% |
| Dec 31, 2021 | 1.64B | -355.32M | -17.82% |
| Dec 31, 2020 | 1.99B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GC Cell | 170.13B |
| HansBiomed | 89.78B |
| ISU Abxis | 66.39B |
| NIBEC | 32.96B |
| Genome & Company | 25.95B |
| S.Biomedics | 16.96B |
| Prestige Biologics | 13.36B |
| Y-Biologics | 3.61B |